EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy of the Once-Daily Tacrolimus Formulation LCPT Compared to the Immediate-Release Formulation in Preventing Early Post-Transplant Diabetes in High-Risk Kidney Transplant Patients: A Randomized, Controlled, Open-Label Pilot Study (EUDRACT: 2017-000718-52)

Wirksamkeit der einmal täglich gegebenen Tacrolimus-Formulierung LCPT im Vergleich zur Immediate-Release-Formulierung zur Prävention eines frühen Posttransplantationsdiabetes bei Hochrisiko-Nierentransplantationspatient:innen: randomisierte, kontrollierte, offene Pilotstudie (EUDRACT: 2017-000718-52)

Armando Torres, Concepción Rodríguez-Adanero, Constantino Fernández-Rivera iD, Domingo Marrero-Miranda, Eduardo de Bonis-Redondo, Aurelio P Rodríguez-Hernández, Lourdes Pérez-Tamajón iD, Ana González-Rinne, Diego Álvarez-Sosa, Alejandra Álvarez-González, Nuria Sanchez-Dorta, Estefanía Pérez-Carreño und 12 weitere

Journal of Clinical Medicine · 20.12.2024 · 13 (24) · 7802

DOI: 10.3390/jcm13247802 ↗

Auf einen Blick

In dieser randomisierten Pilotstudie war die PTDM-Inzidenz unter LCPT und IR-Tac vergleichbar. Für Prädiabetes zeigte sich unter LCPT ein Trend zu niedrigeren Raten.

Fragestellung

Ist LCPT im Vergleich zu Immediate-Release-Tacrolimus bei Hochrisiko-Nierentransplantationspatient:innen mit geringerer PTDM- und PreDM-Inzidenz verbunden?

Methode

Randomisierte, kontrollierte, offene Pilotstudie; de-novo-Immunsuppression mit IR-Tac zweimal täglich oder LCPT einmal täglich; Follow-up 3 Monate.

Ergebnisse

27 Patient:innen erhielten IR-Tac, 25 LCPT. PTDM: 18,5 % (95 %-KI 8,2–36,7 %) vs. 24 % (95 %-KI 11,5–43,4 %), p = 0,7. PreDM: 40,7 % vs. 20 %, p = 0,1.

Schlussfolgerung der Autor:innen

Die potenzielle biologische Aktivität von LCPT zur Prävention glucosemetabolischer Veränderungen bei Risikopatient:innen erfordert weitere Untersuchung.

Kernaussagen

  • PTDM-Inzidenz unter LCPT und IR-Tac vergleichbar
  • PreDM unter LCPT numerisch niedriger
  • Offene Pilotstudie mit 3 Monaten Follow-up

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 20.12.2024. Verfasst von Armando Torres und 23 weiteren Autor:innen. Beteiligte Einrichtung: Nephrology Service, Hospital Universitario de Canarias, 38320 La Laguna, Spain. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nephrology Department at Hospital Universitario de Canarias.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Post-transplant diabetes mellitus (PTDM) and prediabetes (PreDM) are common after renal transplantation and increase the risk of cardiovascular events and mortality. Compared to immediate-release tacrolimus (IR-Tac), the LCPT formulation, with delayed absorption, offers higher bioavailability and a smoother time–concentration curve, potentially reducing beta-cell stress.

Methods

This randomized pilot trial compared de novo immunosuppression with IR-Tac (twice daily) and LCPT (once daily). At-risk recipients (age ≥ 60 years or 18–59 years with metabolic syndrome) were enrolled and followed for 3 months. The primary and secondary outcomes were the incidence of PTDM and PreDM, respectively.

Results

27 patients were randomized to IR-Tac and 25 to LCPT. The incidence of PTDM was comparable between groups [IR Tac: 18.5% (95% CI: 8.2–36.7%) vs. LCPT: 24% (95% CI: 11.5–43.4%); p = 0.7]. Although not statistically significant, the LCPT group exhibited a trend toward a reduction in PreDM incidence [IR-Tac: 40.7% (95% CI: 25–59%) vs. LCPT: 20% (95% CI: 9–39%); p = 0.1]. A sensitivity analysis showed similar results, with no significant differences in cumulative corticosteroid doses or baseline body mass index (BMI) between groups. The LCPT group showed a trend toward higher tacrolimus exposure at the end of the study [trough levels: IR-Tac group 8.3 (6.9–9.2) vs. LCPT group 9.4 (7.4–11.4) ng/mL; p = 0.05)], as well as fewer acute rejection episodes (none vs. three). Delayed graft function was more common in the IR-Tac group (37% vs. 8%; p = 0.01), and the eGFR was lower. Adverse events were comparable between groups.

Conclusions

The potential biological activity of LCPT in preventing glucose metabolic alterations in at-risk patients warrants further investigation.

Schlagwörter

Stichwörter der Autor:innen

LCPT tacrolimusearly-release tacrolimuskidney transplantationpost-transplant diabetespost-transplant prediabetestacrolimus pharmacokinetics

Autor:innen und Institutionen

  • Nephrology Service, Hospital Universitario de Canarias, 38320 La Laguna, Spain.
  • Instituto de Tecnologías Biomédicas (ITB), Universidad de La Laguna, 38206 La Laguna, Spain.
  • Servicio de Nefrología, Complejo Hospitalario Universitario de A Coruña, 15006 La Coruña, Spain.
  • Research Unit, Hospital Universitario de Canarias, 38320 La Laguna, Spain.
  • Central Laboratory, Hospital Universitario de Canarias, 38320 La Laguna, Spain.
  • Pharmacy Service, Hospital Universitario de Canarias, 38320 La Laguna, Spain.

ORCID-Profile: Constantino Fernández-Rivera, Lourdes Pérez-Tamajón, Ana E Rodríguez-Rodríguez

Förderung

  • Nephrology Department at Hospital Universitario de Canarias

Zitieren

APA

Torres, A., Rodríguez-Adanero, C., Fernández-Rivera, C., Marrero-Miranda, D., de Bonis-Redondo, E., Rodríguez-Hernández, A. P., Pérez-Tamajón, L., González-Rinne, A., Álvarez-Sosa, D., Álvarez-González, A., Sanchez-Dorta, N., Pérez-Carreño, E., Díaz-Martín, L., Luis-Lima, S., Rodríguez-Rodríguez, A. E., Vera González, A. M., Romero-Delgado, C., Calvo-Rodríguez, M., Seijo-Bestilleiro, R., …, & Porrini, E. (2024). Efficacy of the Once-Daily Tacrolimus Formulation LCPT Compared to the Immediate-Release Formulation in Preventing Early Post-Transplant Diabetes in High-Risk Kidney Transplant Patients: A Randomized, Controlled, Open-Label Pilot Study (EUDRACT: 2017-000718-52). Journal of Clinical Medicine, 13(24), 7802. https://doi.org/10.3390/jcm13247802

Vancouver

Torres A, Rodríguez-Adanero C, Fernández-Rivera C, Marrero-Miranda D, de Bonis-Redondo E, Rodríguez-Hernández AP, et al. Efficacy of the Once-Daily Tacrolimus Formulation LCPT Compared to the Immediate-Release Formulation in Preventing Early Post-Transplant Diabetes in High-Risk Kidney Transplant Patients: A Randomized, Controlled, Open-Label Pilot Study (EUDRACT: 2017-000718-52). Journal of Clinical Medicine. 2024;13(24):7802. doi:10.3390/jcm13247802

BibTeX
@article{Torres2024,
  author = {Torres, Armando and Rodríguez-Adanero, Concepción and Fernández-Rivera, Constantino and Marrero-Miranda, Domingo and de Bonis-Redondo, Eduardo and Rodríguez-Hernández, Aurelio P and Pérez-Tamajón, Lourdes and González-Rinne, Ana and Álvarez-Sosa, Diego and Álvarez-González, Alejandra and Sanchez-Dorta, Nuria and Pérez-Carreño, Estefanía and Díaz-Martín, Laura and Luis-Lima, Sergio and Rodríguez-Rodríguez, Ana E and Vera González, Antonia María de and Romero-Delgado, Cristina and Calvo-Rodríguez, María and Seijo-Bestilleiro, Rocío and Rodríguez-Jiménez, Consuelo and Prieto López, Manuel Arturo and Rivero-González, Antonio Manuel and Hernández-Marrero, Domingo and Porrini, Esteban},
  title = {Efficacy of the Once-Daily Tacrolimus Formulation LCPT Compared to the Immediate-Release Formulation in Preventing Early Post-Transplant Diabetes in High-Risk Kidney Transplant Patients: A Randomized, Controlled, Open-Label Pilot Study (EUDRACT: 2017-000718-52)},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {24},
  pages = {7802},
  doi = {10.3390/jcm13247802}
}
Kostenlos starten →